

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---------------------------------|-----------------------|---|---|--|
| Cancer | | | | |
| Lymphoma; multiple myeloma (MM) | Proteasome | <p>SAR and <i>in vitro</i> studies identified analogs of the proteasome inhibitor salinosporamide A that could help treat MM or mantle cell lymphoma. In a cancer cell line, one of the analogs was three times more potent than the salinosporamide A parent proteasome inhibitor. Next steps could include testing the analogs in preclinical cancer models.</p> <p>Salinosporamide A is a generic natural product. Velcade bortezomib, a proteasome inhibitor from Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson, is approved to treat MM and mantle cell lymphoma. At least four other companies have proteasome inhibitors in development to treat MM or lymphomas.</p> <p>SciBX 2(39); doi:10.1038/scibx.2009.1470 Published online Oct. 8, 2009</p> | Patent and licensing status unavailable | <p>Nett, M. <i>et al. J. Med. Chem.</i>; published online Sept. 11, 2009; doi:10.1021/jm901098m</p> <p>Contact: Bradley S. Moore, University of California, San Diego, La Jolla, Calif. e-mail: bsmoore@ucsd.edu</p> |